Evaxion (EVAX) CSO Birgitte Rono details extensive warrant holdings

Rhea-AI Filing Summary

Evaxion A/S Chief Scientific Officer Birgitte Rono filed an amended Form 3 to update her equity holdings. The filing lists multiple warrant positions over Evaxion ordinary shares, including warrants exercisable at prices ranging from 0.07 to 5.38 with expirations extending to 2036-12-31. One warrant series relates to a private placement that closed on 2023-12-21, and certain awards vest monthly over 36 months from their initial exercise dates. The amendment also shows direct ownership of 36,765 ordinary shares, giving investors a clearer picture of her current stake.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rono Birgitte

(Last) (First) (Middle)

DR. NEERGAARDS VEJ 5F

(Street)

HORSHOLM DK-2970

(City) (State) (Zip)

DENMARK

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Evaxion A/S [ EVAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
03/18/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	36,765	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants(1)	12/21/2023	12/21/2026	Ordinary Shares	36,765	$0.74	D
Warrants	01/01/2017	12/31/2036	Ordinary Shares	1,152	$0.1	D
Warrants	01/01/2018(2)	12/31/2036	Ordinary Shares	7,092	$0.1	D
Warrants	01/01/2019(2)	12/31/2031	Ordinary Shares	10,440	$0.1	D
Warrants	01/01/2020(2)	12/31/2031	Ordinary Shares	10,692	$0.1	D
Warrants	01/01/2021(2)	12/31/2031	Ordinary Shares	45,000	$5.38	D
Warrants	01/01/2022(2)	12/31/2031	Ordinary Shares	25,000	$2.23	D
Warrants	01/01/2023(2)	12/31/2031	Ordinary Shares	12,500	$0.75	D
Warrants	01/01/2024(2)	12/31/2031	Ordinary Shares	50,000	$0.4	D
Warrants	01/01/2024(2)	12/31/2031	Ordinary Shares	125,000	$0.07	D

Explanation of Responses:

1. Warrants pursuant to private placement that closed 12/21/2023.

2. Vesting is 1/36 per month over 36 months from the initial exercise date indicated.

Remarks:

Exhibit List - Exhibit 24.1 Power of Attorney. This Form 3/A amends the Form 3 filed on March 18, 2026, which reported Ms. Rono's initial holdings using the Issuer's CIK number as an interim measure, pending receipt of Ms. Rono's new filer CIK codes. This Form 3/A has been filed using Ms. Rono's CIK codes and reflects her as the Reporting Owner, with no alteration to her beneficial ownership.

	/s/ Michael Baird, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Evaxion A/S (EVAX) Chief Scientific Officer Birgitte Rono report in this Form 3/A?

She reports updated holdings of warrants and ordinary shares in Evaxion A/S. The filing details several warrant series over ordinary shares plus direct ownership of 36,765 ordinary shares, clarifying her current equity stake as an officer.

How many Evaxion (EVAX) ordinary shares does Birgitte Rono directly own in this Form 3/A?

The Form 3/A shows direct ownership of 36,765 ordinary shares. This figure reflects her reported common equity position separate from warrants, helping investors understand the portion of her stake already in ordinary shares.

What warrant positions are disclosed for Birgitte Rono in Evaxion (EVAX) according to the Form 3/A?

The filing lists multiple warrant holdings over Evaxion ordinary shares, with exercise prices from 0.07 to 5.38 and expirations out to 2036-12-31. Each series specifies the underlying share amount and direct ownership status.

Is any of Birgitte Rono’s Evaxion (EVAX) warrant position tied to a private placement?

Yes. A warrant position referencing 36,765 underlying ordinary shares is noted as issued pursuant to a private placement that closed on 2023-12-21. This footnote links that specific warrant series to the prior financing event.

How do Birgitte Rono’s Evaxion (EVAX) warrants vest according to the Form 3/A footnotes?

The footnotes state that certain awards vest at 1/36 per month over 36 months from the initial exercise date. This means vesting is gradual, with equal monthly portions becoming exercisable across the three-year schedule.